Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer’s disease

Acta Neuropathologica

Volumn 129, Issue 4, 2015, Pages 541-563

  Ádori, Csaba ^a   Glück, Laura ^b   Barde, Swapnali ^a   Yoshitake, Takashi ^a   Kovacs, Gabor G ^c   Mulder, Jan ^a   Maglóczky, Zsófia ^d   Havas, László ^e   Bölcskei, Kata ^f   Mitsios, Nicholas ^a   Uhlén, Mathias ^g   Szolcsányi, János ^f   Kehr, Jan ^a   Rönnbäck, Annica ^a   Schwartz, Thue ^h   Rehfeld, Jens F ⁱ   Harkany, Tibor ^a,j   Palkovits, Miklós ^d,k   Schulz, Stefan ^b   Hökfelt, Tomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e Szent Borbála Hospital   (Hungary)

^f UNIVERSITY OF PÉCS   (Hungary)

^g ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^h Capital Region   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j Medical University of Vienna   (Austria)

^k SEMMELWEIS UNIVERSITY   (Hungary)

more..

Author keywords

Alzheimer s disease; Co existence; Depression; Neurodegeneration; Neuropeptide; Neurotransmitter; Noradrenaline

Indexed keywords

AMYLOID BETA PROTEIN; BIOGENIC AMINE; CARBOCYANINE; NORADRENALIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; TAU PROTEIN; TO-PRO-3; TYROSINE 3 MONOOXYGENASE;

AGE; AGED; ALZHEIMER DISEASE; ANIMAL; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LOCUS CERULEUS; MALE; METABOLISM; MIDDLE AGED; MOUSE; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TEMPORAL LOBE; TRANSGENIC MOUSE;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOGENIC MONOAMINES; CARBOCYANINES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LOCUS COERULEUS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEURONS; NOREPINEPHRINE; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN; TAU PROTEINS; TEMPORAL LOBE; TYROSINE 3-MONOOXYGENASE;

EID: 84940004181     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1394-3     Document Type: Article

References (119)

1. Adams JC (1992) Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 40:1457–1463
2. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135:216–223
3. Adori C, Ando RD, Szekeres M, Gutknecht L, Kovacs GG, Hunyady L, Lesch KP, Bagdy G (2011) Recovery and aging of serotonergic fibers after single and intermittent MDMA treatment in Dark Agouti rat. J Comp Neurol 519:2353–2378. doi:10.1002/cne.22631
4. Adori C, Low P, Ando RD, Gutknecht L, Pap D, Truszka F, Takacs J, Kovacs GG, Lesch KP, Bagdy G (2011) Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat. Psychopharmacology 213:377–391. doi:10.1007/s00213-010-2041-2
5. Allen JP, Canty AJ, Schulz S, Humphrey PP, Emson PC, Young HM (2002) Identification of cells expressing somatostatin receptor 2 in the gastrointestinal tract of Sstr2 knockout/lacZ knockin mice. J Comp Neurol 454:329–340. doi:10.1002/cne.10466
6. Allen JP, Hathway GJ, Clarke NJ, Jowett MI, Topps S, Kendrick KM, Humphrey PP, Wilkinson LS, Emson PC (2003) Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur J Neurosci 17:1881–1895
7. Armstrong DM, Hersh LB, Gage FH (1988) Morphologic alterations of cholinergic processes in the neocortex of aged rats. Neurobiol Aging 9:199–205
8. Aston-Jones G (2004) Locus coeruleus, A5 and A7 noradrenergic cell groups. In: Paxinos G (ed) The rat nervous system, vol 3rd edn. Elsevier, Amsterdam, pp 259–264
9. Aston-Jones G, Rajkowski J, Kubiak P, Valentino RJ, Shipley MT (1996) Role of the locus coeruleus in emotional activation. Prog Brain Res 107:379–402
10. Attems J, Thal DR, Jellinger KA (2012) The relationship between subcortical tau pathology and Alzheimer’s disease. Biochem Soc Trans 40:711–715. doi:10.1042/BST20120034
11. Berridge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42:33–84
12. Bondareff W, Mountjoy CQ, Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 32:164–168
13. Braak H, Del Tredici K (2011) Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121:589–595. doi:10.1007/s00401-011-0825-z
14. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121:171–181. doi:10.1007/s00401-010-0789-4
15. Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr Opin Neurol 25:708–714. doi:10.1097/WCO.0b013e32835a3432
16. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79
17. Bremner JD, Krystal JH, Southwick SM, Charney DS (1996) Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23:28–38. doi:10.1002/(SICI)1098-2396(199605)23:1<28:AID-SYN4>3.0.CO;2-J
18. Bremner JD, Krystal JH, Southwick SM, Charney DS (1996) Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23:39–51. doi:10.1002/(SICI)1098-2396(199605)23:1<39:AID-SYN5>3.0.CO;2-I
19. Burbach JP (2010) Neuropeptides from concept to online database http://www.neuropeptides.nl. Eur J Pharmacol 626:27–48. doi:10.1016/j.ejphar.2009.10.015
20. Burgos-Ramos E, Hervas-Aguilar A, Aguado-Llera D, Puebla-Jimenez L, Hernandez-Pinto AM, Barrios V, Arilla-Ferreiro E (2008) Somatostatin and Alzheimer’s disease. Mol Cell Endocrinol 286:104–111. doi:10.1016/j.mce.2008.01.014
21. Carpentier V, Vaudry H, Laquerriere A, Tayot J, Leroux P (1996) Distribution of somatostatin receptors in the adult human brainstem. Brain Res 734:135–148
22. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 287:373–392. doi:10.1002/cne.902870308
23. Chessell IP, Black MD, Feniuk W, Humphrey PP (1996) Operational characteristics of somatostatin receptors mediating inhibitory actions on rat locus coeruleus neurones. Br J Pharmacol 117:1673–1678
24. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56:1135–1140
25. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE (1981) Reduced dopamine-beta-hydroxylase activity in Alzheimer’s disease. Br Med J 282:93–94
26. Dahlström A, Fuxe K (1964) Evidence for the existence of monoamine neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brainstem neurons. Acta Physiol Scand 62:1–55
27. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 288:279–280
28. De Martino C, Zamboni L (1967) Silver methenamine stain for electron microscopy. J Ultrastruct Res 19:273–282
29. Doraiswamy PM, Xiong GL (2006) Pharmacological strategies for the prevention of Alzheimer’s disease. Expert Opin Pharmacother 7:1–10. doi:10.1517/14656566.7.1.S1
30. Dournaud P, Delaere P, Hauw JJ, Epelbaum J (1995) Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer’s disease. Neurobiol Aging 16:817–823
31. Dutar P, Vaillend C, Viollet C, Billard JM, Potier B, Carlo AS, Ungerer A, Epelbaum J (2002) Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice. Neuroscience 112:455–466
32. Engin E, Stellbrink J, Treit D, Dickson CT (2008) Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 157:666–676. doi:10.1016/j.neuroscience.2008.09.037
33. Engin E, Treit D (2009) Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors. Psychopharmacology 206:281–289. doi:10.1007/s00213-009-1605-5
34. Epelbaum J et al (1986) Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27:63–100. doi:10.1016/0301-0082(86)90012-2
35. Epelbaum J, Bluet-Pajot MT, Llorens-Cortes C, Kordon C, Mounier F, Senut MC, Videau C (1990) 125I-[Tyr0, D-Trp8]somatostatin-14 binding sites in the locus coeruleus of the rat are located on both ascending and descending projecting noradrenergic cells. Peptides 11:21–27
36. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C (2009) Somatostatin, Alzheimer’s disease and cognition: an old story coming of age? Prog Neurobiol 89:153–161. doi:10.1016/j.pneurobio.2009.07.002
37. Farris TW, Butcher LL, Oh JD, Woolf NJ (1995) Trophic-factor modulation of cortical acetylcholinesterase reappearance following transection of the medial cholinergic pathway in the adult rat. Exp Neurol 131:180–192
38. Ferriero DM, Sheldon RA, Messing RO (1994) Somatostatin enhances nerve growth factor-induced neurite outgrowth in PC12 cells. Brain Res Dev Brain Res 80:13–18
39. Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63:844–914
40. Fuxe K, Hökfelt T, Ungerstedt U (1970) Central monoaminergic tracts. In: Clark WG, Del Guidice J (eds) Principles of Psychopharmacology, Academic Press, London, pp 87–96
41. Gagne C, Moyse E, Kocher L, Bour H, Pujol JF (1990) Light-microscopic localization of somatostatin binding sites in the locus coeruleus of the rat. Brain Res 530:196–204
42. Gahete MD, Rubio A, Duran-Prado M, Avila J, Luque RM, Castano JP (2010) Expression of somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer’s disease patients. J Alzheimers Dis 20:465–475. doi:10.3233/JAD-2010-1385
43. Gaspar P, Berger B, Febvret A, Vigny A, Henry JP (1989) Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J Comp Neurol 279:249–271. doi:10.1002/cne.902790208
44. German DC, Manaye KF, White CL 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667–676. doi:10.1002/ana.410320510
45. German DC, Nelson O, Liang F, Liang CL, Games D (2005) The PDAPP mouse model of Alzheimer’s disease: locus coeruleus neuronal shrinkage. J Comp Neurol 492:469–476. doi:10.1002/cne.20744
46. Greenberg MS, Tanev K, Marin MF, Pitman RK (2014) Stress, PTSD, and dementia. Alzheimers Dement 10:S155–S165. doi:10.1016/j.jalz.2014.04.008
47. Grzanna R, Fritschy JM (1991) Efferent projections of different subpopulations of central noradrenaline neurons. Prog Brain Res 88:89–101
48. Haglund M, Sjobeck M, Englund E (2006) Locus ceruleus degeneration is ubiquitous in Alzheimer’s disease: possible implications for diagnosis and treatment. Neuropathology 26:528–532
49. Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J, Weinshenker D, Heneka MT (2013) Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psychiatry 73:454–463. doi:10.1016/j.biopsych.2012.06.013
50. Harro J, Oreland L, Vasar E, Bradwejn J (1995) Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol 5:447–455
51. Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, Keszthelyi D, Szoke E, Toth DM, Sandor Z, Kereskai L, Pozsgai G, Allen JP, Emson PC, Markovics A, Szolcsanyi J (2009) Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. Proc Natl Acad Sci USA 106:13088–13093. doi:10.1073/pnas.0900681106
52. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP (2010) Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107:6058–6063. doi:10.1073/pnas.0909586107
53. Horgan J, Miguel-Hidalgo JJ, Thrasher M, Bissette G (2007) Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer’s disease. J Alzheimers Dis 12:115–127
54. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O’Carroll AM, Patel YC, Schonbrunn A, Taylor JE et al (1995) Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16:86–88. doi:10.1016/S0165-6147(00)88988-9
55. Inoue M, Nakajima S, Nakajima Y (1988) Somatostatin induces an inward rectification in rat locus coeruleus neurones through a pertussis toxin-sensitive mechanism. J Physiol 407:177–198
56. Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F (2012) Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp JoVE. doi:10.3791/3620
57. Kehr J, Yoshitake T (2006) Monitoring brain chemical signals by microdialysis. In: Grimes CA, Dickey EC, Pishko MV (eds) Encyclopedia of Sensors, vol 6. American Scientific Publishers, USA, pp 287–312
58. Kowall NW, Beal MF (1988) Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer’s disease. Ann Neurol 23:105–114. doi:10.1002/ana.410230202
59. Krantic S, Robitaille Y, Quirion R (1992) Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer’s disease. Brain Res 573:299–304
60. Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A, Figura S, Stoll M, Schwartz S, Pape HC, Schultze JL, Weinshenker D, Heneka MT (2014) Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J Neurosc 34:8845–8854. doi:10.1523/JNEUROSCI.4027-13.2014
61. Laboratory J http://jaxmice.jax.org/strain/005844.html
62. Le Maitre E, Barde SS, Palkovits M, Diaz-Heijtz R, Hokfelt TG (2013) Distinct features of neurotransmitter systems in the human brain with focus on the galanin system in locus coeruleus and dorsal raphe. Proc Natl Acad Sci USA 110:E536–E545. doi:10.1073/pnas.1221378110
63. Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237:1154–1162
64. Lin LC, Sibille E (2013) Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front Pharmacol 4:110. doi:10.3389/fphar.2013.00110
65. Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S (1980) Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry 136:533–541
66. Marino MD, Bourdelat-Parks BN, Cameron Liles L, Weinshenker D (2005) Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav Brain Res 161:197–203. doi:10.1016/j.bbr.2005.02.005
67. Masaya Tohyama KT (1998) Atlas of neuroactive substances and their receptors in the rat. Oxford University Press, New York
68. Masuko S, Nakajima Y, Nakajima S, Yamaguchi K (1986) Noradrenergic neurons from the locus ceruleus in dissociated cell culture: culture methods, morphology, and electrophysiology. J Neurosci 6:3229–3241
69. McCarthy AD, Owens IJ, Bansal AT, McTighe SM, Bussey TJ, Saksida LM (2011) FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer’s disease. Pharmacol Biochem Behav 98:76–80. doi:10.1016/j.pbb.2010.11.019
70. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, Szot P (2011) Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s disease. Brain Res 1373:240–252. doi:10.1016/j.brainres.2010.12.015
71. Melander T, Hökfelt T, Rokaeus A, Cuello AC, Oertel WH, Verhofstad A, Goldstein M (1986) Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J Neurosci 6:3640–3654
72. Moore RY, Bloom FE (1979) Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci 2:113–168. doi:10.1146/annurev.ne.02.030179.000553
73. Morilak DA, Barrera G, Echevarria DJ, Garcia AS, Hernandez A, Ma S, Petre CO (2005) Role of brain norepinephrine in the behavioral response to stress. Prog Neuropsychopharmacol Biol Psychiatry 29:1214–1224. doi:10.1016/j.pnpbp.2005.08.007
74. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE (1985) Somatostatin immunoreactivity in neuritic plaques of Alzheimer’s patients. Nature 314:90–92
75. Murayama S, Saito Y (2004) Neuropathological diagnostic criteria for Alzheimer’s disease. Neuropathology 24:254–260
76. Nemeroff CB, Kizer JS, Reynolds GP, Bissette G (1989) Neuropeptides in Alzheimer’s disease: a postmortem study. Regul Pept 25:123–130
77. Nishimura A, Ueda S, Takeuchi Y, Matsushita H, Sawada T, Kawata M (1998) Vulnerability to aging in the rat serotonergic system. Acta Neuropathol 96:581–595
78. Norberg KA (1967) Transmitter histochemistry of the sympathetic adrenergic nervous system. Brain Res 5:125–170
79. Olpe HR, Steinmann MW, Pozza MF, Haas HL (1987) Comparative investigations on the actions of ACTH1-24, somatostatin, neurotensin, substance P and vasopressin on locus coeruleus neuronal activity in vitro. Naunyn Schmiedebergs Arch Pharmacol 336:434–437
80. Palkovits M, Epelbaum J, Tapia-Arancibia L, Kordon C (1982) Somatostatin in catecholamine-rich nuclei of the brainstem. Neuropeptides 3:139–144
81. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Res 401:231–238
82. Paxinos G, Huang XF (1995) Atlas of the human brainstem. Academic Press Inc., San Diego
83. Peng I, Binder LI, Black MM (1986) Biochemical and immunological analyses of cytoskeletal domains of neurons. J Cell Biol 102:252–262
84. Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J (2006) Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer’s disease. Neurobiol Aging 27:1658–1672. doi:10.1016/j.neurobiolaging.2005.09.022
85. Robertson IH (2013) A noradrenergic theory of cognitive reserve: implications for Alzheimer’s disease. Neurobiol Aging 34:298–308. doi:10.1016/j.neurobiolaging.2012.05.019
86. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 104:13804–13809. doi:10.1073/pnas.0702753104
87. Ronnback A, Sagelius H, Bergstedt KD, Naslund J, Westermark GT, Winblad B, Graff C (2012) Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol Aging 33(831):e811–e839. doi:10.1016/j.neurobiolaging.2011.07.012
88. Ronnback A, Zhu S, Dillner K, Aoki M, Lilius L, Naslund J, Winblad B, Graff C (2011) Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol Aging 32:280–292. doi:10.1016/j.neurobiolaging.2009.02.021
89. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL (1980) Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 20:373–377
90. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11:434–439. doi:10.1038/nm1206
91. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617. doi:10.1016/j.nbd.2004.10.022
92. Schalling M, Seroogy K, Hökfelt T, Chai SY, Hallman H, Persson H, Larhammar D, Ericsson A, Terenius L, Graffi J et al (1988) Neuropeptide tyrosine in the rat adrenal gland–immunohistochemical and in situ hybridization studies. Neuroscience 24:337–349
93. Schatzberg F, Schildkraut JJ (1995) Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology. Raven Press, New York, pp 911–920
94. Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C (2012) Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 29:793–806. doi:10.1007/s40266-012-0012-5
95. Shi TJ, Xiang Q, Zhang MD, Barde S, Kai-Larsen Y, Fried K, Josephson A, Gluck L, Deyev SM, Zvyagin AV, Schulz S, Hokfelt T (2014) Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain. Mol Pain 10:12. doi:10.1186/1744-8069-10-12
96. Stengel A, Rivier J, Tache Y (2013) Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes. Peptides 42:70–77. doi:10.1016/j.peptides.2012.12.022
97. Szabadi E (2013) Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol 27:659–693. doi:10.1177/0269881113490326
98. Szot P (2012) Common factors among Alzheimer’s disease, Parkinson’s disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia 53(Suppl 1):61–66. doi:10.1111/j.1528-1167.2012.03476.x
99. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2006) Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosc 26:467–478. doi:10.1523/JNEUROSCI.4265-05.2006
100. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V (1983) Galanin—a novel biologically active peptide from porcine intestine. FEBS Lett 164:124–128. doi:10.1016/0014-5793(83)80033-7
101. Thoss VS, Perez J, Duc D, Hoyer D (1995) Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain. Neuropharmacology 34:1673–1688
102. Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, Mutoh S (2005) FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol 527:111–120. doi:10.1016/j.ejphar.2005.10.022
103. Tomlinson BE, Irving D, Blessed G (1981) Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 49:419–428
104. Toppila J, Niittymaki P, Porkka-Heiskanen T, Stenberg D (2000) Intracerebroventricular and locus coeruleus microinjections of somatostatin antagonist decrease REM sleep in rats. Pharmacol Biochem Behav 66:721–727
105. Toth K, Eross L, Vajda J, Halasz P, Freund TF, Magloczky Z (2010) Loss and reorganization of calretinin-containing interneurons in the epileptic human hippocampus. Brain 133:2763–2777. doi:10.1093/brain/awq149
106. Ueda S, Aikawa M, Ishizuya-Oka A, Yamaoka S, Koibuchi N, Yoshimoto K (2000) Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle. Neuroscience 95:389–398
107. Vale W, Brazeau P, Rivier C, Brown M, Boss B, Rivier J, Burgus R, Ling N, Guillemin R (1975) Somatostatin. Recent Prog Horm Res 31:365–397
108. van de Nes JA, Konermann S, Nafe R, Swaab DF (2006) Beta-protein/A4 deposits are not associated with hyperphosphorylated tau in somatostatin neurons in the hypothalamus of Alzheimer’s disease patients. Acta Neuropathol 111:126–138. doi:10.1007/s00401-005-0018-8
109. van Luijtelaar MG, Steinbusch HW, Tonnaer JA (1988) Aberrant morphology of serotonergic fibers in the forebrain of the aged rat. Neurosci Lett 95:93–96
110. van Luijtelaar MG, Tonnaer JA, Steinbusch HW (1992) Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol Aging 13:201–215
111. Vepsalainen S, Helisalmi S, Koivisto AM, Tapaninen T, Hiltunen M, Soininen H (2007) Somatostatin genetic variants modify the risk for Alzheimer’s disease among Finnish patients. J Neurol 254:1504–1508. doi:10.1007/s00415-007-0539-2
112. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J (2008) Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol 286:75–87. doi:10.1016/j.mce.2007.09.007
113. Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, L’Heritier A, Kopp C, Potier B, Billard J, Schaeffer J, Smith RG, Rohrer SP, Wilkinson H, Zheng H, Epelbaum J (2000) Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur J Neurosci 12:3761–3770
114. Watabe Y, Yoshimoto K, Eguchi M, Ueda S (2005) Degeneration of monoaminergic fibers in the aged micrencephalic rat. Neurosci Lett 385:82–86. doi:10.1016/j.neulet.2005.05.020
115. Weinshenker D (2008) Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 5:342–345
116. Xu ZQ, Shi TJ, Hökfelt T (1998) Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J Comp Neurol 392:227–251
117. Xue S, Jia L, Jia J (2009) Association between somatostatin gene polymorphisms and sporadic Alzheimer’s disease in Chinese population. Neurosci Lett 465:181–183. doi:10.1016/j.neulet.2009.09.002
118. Yeung M, Treit D (2012) The anxiolytic effects of somatostatin following intra-septal and intra-amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903. Pharmacol Biochem Behav 101:88–92. doi:10.1016/j.pbb.2011.12.012
119. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341